TAG:
diagnostic assays
Columbia/HCA, AmeriPath, Epitope, STC Technologies, Quest Diagnostics
By Robert Michel | From the Volume VII No. 8 – May 30, 2000 Issue
COLUMBIA/HCA GETS NEW NAME; ACQUIRES FOUR LONDON HOSPITALS NOW THAT IT HAS A SETTLEMENT with the federal government on civil claims of Medicare fraud, expect a rapid cascade of changes at Columbia/HCA Healthcare Corporation, the nation’s largest for-profit hospital company…
Quest to Pay $1.27 Billion To Buy SB’s Lab Division
By Robert Michel | From the Volume VI No. 3 – February 22, 1999 Issue
CEO SUMMARY: Consolidation is the story of the clinical laboratory industry during the 1990s. The decade will close out with the granddaddy laboratory consolidation of them all! When Quest Diagnostics Incorporated completes its acquisition of SmithKline Beecham Clinical Laboratories later…
DARK REPORT Picks 1998’s Ten Biggest Lab Stories
By Robert Michel | From the Volume VI No. 1 – January 11, 1999 Issue
CEO SUMMARY: Our story picks for 1998 demonstrate a broad range of subjects. Each affects laboratories and pathology practices in significant ways and should be used to trigger appropriate management strategies. Two essential themes among this year’s ten biggest lab stories: continued d…
Chiron Is Biotech Firm, Respected For Innovation
By Robert Michel | From the Volume V No. 13 – September 28, 1998 Issue
CEO SUMMARY: Chiron is respected for its leadership in branched DNA and viral load technologies. The company had high expectations for its diagnostics group, particularly after its purchase of Ciba Corning. But rapid consolidation of the diagnostics industry changed Chiron’s opportunity…
“September 28, 1998 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume V No. 13 – September 28, 1998 Issue
Just days ago, Bayer AG announced one of the largest drug-discovery alliances ever created. Bayer will pay Millennium Pharmaceuticals, Inc. $465 million. In return, over a six-year period, Millennium will use genomics techniques to identify cures for various diseases…
Pharmacogenomics Is The Coming Wave
By Robert Michel | From the Volume V No. 12 – September 8, 1998 Issue
CEO SUMMARY: It may be gloom and doom today in the clinical laboratory industry, but long term prospects for diagnostic testing are brightening. Increased understanding of human genetics drives new discoveries about how and why the same drug affects individuals differently. Biotech compan…
Genetic Testing Almost Accented In Market Place
By Robert Michel | From the Volume V No. 12 – September 8, 1998 Issue
CEO SUMMARY: Advances in molecular and genetic science have generated the first generation of diagnostic assays for clinical use. As these assays reach the public, acceptance is not immediate. Obstacles are many: ethical, cultural, clinical, and economic. Oncormed’s experience during th…
DIANON Shoots At Urocor, Makes Unwelcome Offer
By Robert Michel | From the Volume V No. 12 – September 8, 1998 Issue
CEO SUMMARY: It pays to know your friends. Last month DIANON Systems announced an unsolicited offer to acquire UroCor. The offer, following months of ongoing discussions between the two companies, was clearly unwelcome at UroCor. Both companies are pushing hard to evolve disease managemen…
“Corporatized” Healthcare Encountering Big Losses
By Robert Michel | From the Volume V No. 11 – August 17, 1998 Issue
CEO SUMMARY: When the clinical laboratory industry found itself losing hundreds of millions of dollars in recent years, few people imagined that billion-dollar HMO and PPM companies would soon experience similar losses. Current trends in the managed care marketplace indicate that problems…
“Disease Management” Firms, Niche Labs Release Financials
By Robert Michel | From the Volume V No. 8 – June 15, 1998 Issue
Two DISEASE MANAGEMENT FIRMS enjoyed strong revenue growth during the first quarter of 1998. UroCor, Inc. and Impath Inc. posted revenue increases of 31% and 49%, respectively, over first quarter 1997. UroCor is the disease management company which serves urologists…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized